The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal
Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal compared with chemotherapy, use relevant biomarkers to evaluate the efficacy of chemotherapy and seek for patients with Her-2 negative and metastatic adenocarcinoma of the stomach / gastroesophageal surviving benefit from surgical treatment after the FLOT regimen conversion therapy.
Adenocarcinoma of the Stomach / Gastroesophageal
DRUG: FLOT regimen chemotherapy|PROCEDURE: D2 gastric and imaging metastases resection
Progression-free Survival (PFS), From date of randomization until the date of first documented progression or date of death from any cause, up to 2 year
Overall survival(OS), the first day of treatment to death or last survival confirm date, up to 24 months|Objective Response Rate (ORR), From date of randomization until the date of death from any cause, up to 1 year|R0 resection rate, Tumor tissue was completely resected as a percentage of all surgical patients, up to 1 year
Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal compared with chemotherapy, use relevant biomarkers to evaluate the efficacy of chemotherapy and seek for patients with Her-2 negative and metastatic adenocarcinoma of the stomach / gastroesophageal surviving benefit from surgical treatment after the FLOT regimen conversion therapy.